Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

van der Mijn JC, Laursen KB, Fu L, Khani F, Dow LE, Nowak DG, et al. Novel genetically engineered mouse models for clear cell renal cell carcinoma. Sci Rep. 2023;13(1):8246.

Imada EL, Wilks C, Langmead B, Marchionni L. REPAC: analysis of alternative polyadenylation from RNA-sequencing data. Genome Biol. 2023;24(1):22.

Suben J, Goyal A, Rao R, Sung S. Diagnostic implication of extracellular mucin in pancreatic/biliary brushing and stent cytology. Cancer Cytopathol. 2023;131(6):360-364.

Shen B, Saito A, Ueda A, Fujita K, Nagamatsu Y, Hashimoto M, et al. Development of multiple AI pipelines that predict neoadjuvant chemotherapy response of breast cancer using H&E-stained tissues. J Pathol Clin Res. 2023;9(3):182-194.

Chadburn A. Post-transplant lymphoproliferative disorders (PTLD) in adolescents and young adults: A category in need of definition. Semin Diagn Pathol. 2023;40(6):401-407.

Zeng X, Yang M, Ye T, Feng J, Xu X, Yang H, et al. Mitochondrial GRIM-19 loss in parietal cells promotes spasmolytic polypeptide-expressing metaplasia through NLR family pyrin domain-containing 3 (NLRP3)-mediated IL-33 activation via a reactive oxygen species (ROS) -NRF2- Heme oxygenase-1(HO-1)-NF-кB axis. Free Radic Biol Med. 2023;202:46-61.

Rogerson D, Alkelai A, Giordano J, Pantrangi M, Hsiao M-, Nhan-Chang C-, et al. Investigation into the genetics of fetal congenital lymphatic anomalies. Prenat Diagn. 2023;43(6):703-716.

Martinez-Ordoñez A, Duran A, Ruiz-Martinez M, Cid-Diaz T, Zhang X, Han Q, et al. Hyaluronan driven by epithelial aPKC deficiency remodels the microenvironment and creates a vulnerability in mesenchymal colorectal cancer. Cancer Cell. 2023;41(2):252-271.e9.

Mavragani CP, Kirou KA, Seshan SV, Crow MK. Type I interferon and neutrophil transcripts in lupus nephritis renal biopsies: clinical and histopathological associations. Rheumatology (Oxford). 2023;62(7):2534-2538.

Kim JW, McKay RR, Radke MR, Zhao S, Taplin M-, Davis NB, et al. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2023;41(4):871-880.